Diminished ovarian reserve. Female infertility associated with anovulation
Conditions
Interventions
Intervention 1: Intervention group: 5 mililiter of menstrual blood sample will be collected from patients with menstrual cup. Mesenchymal cells will be isolated and cultured from a menstrual blood sam
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 42 Years
Inclusion criteria
Inclusion criteria: Patients aged 20-42 Years Body mass index (BMI) below 30 (kilograms per square meters) Diagnosed diminished ovarian reserve (DOR) Antral follicles below 7 Anti Mullerian Hormone (AMH) below 1.1 nanogram per mililiter (ng/ml) Premature ovarian insufficiency (POI) Unovulation or amnehorreha
Exclusion criteria
Exclusion criteria: Abnormal shape of the uterus on Hysterosalpingography (HSG) or hysteroscopy Hematologic or immunologic diseases Hormonal disturbances Chromosomal and genetics abnormalities Pregnant patients Obstruction of fallopian tubes on Hysterosalpingography or laparoscopy Patients affected by Thyroid disease Patients affected by diabetes Chronic malignancies Chronic pelvic pain Infertility due to severe male factor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estradiol rate of change. Timepoint: 2 weeks before injection and 1 to 3 months after injection. Method of measurement: ELISA diagnostic kit.;The ovarian follicle growth rate of change. Timepoint: 2 weeks before injection and 1 to 3 months after injection. Method of measurement: Ultrasound.;Oocyte quality rate of change. Timepoint: 2 weeks before injection and 1 to 3 months after injection. Method of measurement: Oocyte classification based on presence or absence of polar body and nucleolus.;Follicle Stimulating Hormone (FSH) rate of change. Timepoint: 2 weeks before injection and 1 to 3 months after injection. Method of measurement: ELISA diagnostic kit.;Anti Mullerian Hormone (AMH) rate of change. Timepoint: 2 weeks before injection and 1 to 3 months after injection. Method of measurement: ELISA diagnostic kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pregnancy rate. Timepoint: 1 to 3 months after injection and 12 weeks after pregnancy. Method of measurement: Beta-Human Chorionic Gonadotropin(B HCG) test, Ultrasound.;Live newborn birth rate. Timepoint: 9 to 12 months after injection. Method of measurement: Follow up.;Abortion rate. Timepoint: 1 to 9 month after pregnancy. Method of measurement: Ultrasound, follow up. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShabanali Khodashenas Limoni
Mazandaran University of Medical Sciences
Outcome results
None listed